TABLE 3.

Receiving treatment by characteristics of the provider and hospital

Variable	Antenatal corticosteroid for fetal lung maturity (n = 500 eligible),a n (%)	Progesterone for prevention of preterm birth (n = 753 eligible),b n (%)	Magnesium sulfate for neuroprotection (n = 181 eligible),c n (%)
Hospital annual delivery volume
Tertile 1	225 (92.6)	110 (36.2)	53 (68.0)
Tertile 2	162 (92.6)	118 (44.7)	55 (72.4)
Tertile 3	76 (92.7)	64 (34.6)	21 (77.8)
Hospital availability of maternal-fetal medicine 24/7
No	31 (83.8)d	48 (47.1)	8 (61.5)
Yes	432 (93.3)d	244 (37.5)	121 (72.0)
Attending specialty
General obstetrics	221 (91.3)	179 (38.2)	60 (69.8)
Maternal-fetal medicine	242 (93.8)	113 (39.8)	69 (72.6)
Attending years since graduated medical school
0–9.9 (includes no attending at delivery)	102 (93.6)d	56 (38.9)	31 (73.8)
10–14.9	113 (96.6)d	70 (40.9)	32 (65.3)
15–19.9	94 (94.0)d	50 (36.5)	23 (74.2)
20–24.9	37 (78.7)d	35 (35.4)	8 (72.7)
≥25	115 (92.0)d	77 (40.3)	34 (72.3)

^aPatients eligible for antenatal corticosteroid for fetal lung maturity were those who delivered in the labor and delivery department before 34 weeks of gestation and delivered 4 or more hours after admission;

^bPatients eligible for progesterone for the prevention of preterm birth were those who delivered in the labor and delivery department with a singleton pregnancy, with a history of a prior spontaneous preterm delivery, who had at least 2 prenatal care visits, and whose pregnancy was dated by a first- or second-trimester ultrasound or had assisted reproductive technology;

^cPatients eligible for magnesium sulfate for neuroprotection were those who delivered in the labor and delivery department before 32 weeks of gestation, did not have gestational hypertension or pre-eclampsia, and delivered 4 or more hours after admission;

^dStatistically significant χ² or Fisher exact test (P < .05).